Structural and Functional Study of Potassium Channel Inhibitor Hstx1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Charybdotoxin and Noxiustoxin, Two Homologous Peptide Inhibitors of the K+(Ca2+) Channel
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 226, number 2, 280-284 FEB 05447 January 1988 Charybdotoxin and noxiustoxin, two homologous peptide inhibitors of the K+(Ca2+) channel Hector H. Valdivia*, Jeffrey S. Smith*, Brian M. Martin+, Roberto Coronado* and Lourival D. Possani*’ *Department of Physiology and Molecular Biophysics, Baylor College of Medicine, I Baylor Plaza, Houston, TX 77030, +National Institute of Mental Health, Molecular Neurogenetics Unit, Clinical Neuroscience Branch, Building IO 3016. NIH, Bethesda, MD 20892, USA and “Departamento de Bioquimica, Centro de Investigation sobre Ingenieria Genetica y Biotecnologia. Universidad National Autonoma de Mexico. Apartado Postal 510-3 Cuernavaca, Morelos 62271, Mexico Received 30 October 1987 We show that noxiustoxin (NTX), like charybdotoxin (CTX) described by others, affects CaZt-activated K+ channels of skeletal muscle (K+(Ca2+) channels). Chemical characterization of CTX shows that it is similar to NTX. Although the amino-terminal amino acid of CTX is not readily available, the molecule was partially sequenced after CNBr cleavage. A decapeptide corresponding to the C-terminal region of NTX shows 60% homology to that of CTX, maintaining the cysteine residues at the same positions. While CTX blocks the K+(Ca2+) channels with a & of 1-3 nM, for NTX it is approx. 450 nM. Both peptides can interact simultaneously with the same channel. NTX and CTX promise to be good tools for channel isolation. -
Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of
Short Communication iMedPub Journals 2018 www.imedpub.com Journal of Molecular Sciences Vol.2 No.1:6 Animal Venom Derived Toxins are Novel Upadhyay RK* Analgesics for Treatment of Arthritis Department of Zoology, DDU Gorakhpur University, Gorakhpur, UP, India Abstract *Corresponding authors: Ravi Kant Upadhyay Present review article explains use of animal venom derived toxins as analgesics of the treatment of chronic pain and inflammation occurs in arthritis. It is a [email protected] progressive degenerative joint disease that put major impact on joint function and quality of life. Patients face prolonged inappropriate inflammatory responses and bone erosion. Longer persistent chronic pain is a complex and debilitating Department of Zoology, DDU Gorakhpur condition associated with a large personal, mental, physical and socioeconomic University, Gorakhpur, UttarPradesh, India. burden. However, for mitigation of inflammation and sever pain in joints synthetic analgesics are used to provide quick relief from pain but they impose many long Tel: 9838448495 term side effects. Venom toxins showed high affinity to voltage gated channels, and pain receptors. These are strong inhibitors of ion channels which enable them as potential therapeutic agents for the treatment of pain. Present article Citation: Upadhyay RK (2018) Animal Venom emphasizes development of a new class of analgesic agents in form of venom Derived Toxins are Novel Analgesics for derived toxins for the treatment of arthritis. Treatment of Arthritis. J Mol Sci. Vol.2 No.1:6 Keywords: Analgesics; Venom toxins; Ion channels; Channel inhibitors; Pain; Inflammation Received: February 04, 2018; Accepted: March 12, 2018; Published: March 19, 2018 Introduction such as the back, spine, and pelvis. -
K Channels As Targets for Specific Immunomodulation
Review TRENDS in Pharmacological Sciences Vol.25 No.5 May 2004 K1 channels as targets for specific immunomodulation K. George Chandy1, Heike Wulff2, Christine Beeton1, Michael Pennington3, George A. Gutman1 and Michael D. Cahalan1 1Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA 2Department of Pharmacology and Toxicology, University of California, Davis, CA 95616, USA 3Bachem Bioscience, King of Prussia, PA 19406, USA 21 The voltage-gated Kv1.3 channel and the Ca -activated gene encodes the lymphocyte KV channel [8,9].An IKCa1 K1 channel are expressed in T cells in a distinct intermediate-conductance Ca2þ-activated Kþ channel pattern that depends on the state of lymphocyte acti- was identified in T cells in 1992 [10–12], and shown to vation and differentiation. The channel phenotype be a product of the KCNN4 (IKCa1, KCa3.1; http://www. changes during the progression from the resting to the iuphar-db.org/iuphar-ic/KCa.html) gene in 1997 [13]. activated cell state and from naı¨ve to effector memory Subsequent studies by our group identified calmodulin cells, affording promise for specific immunomodulatory as the Ca2þ sensor of the IKCa1 channel [14]. The salient actions of K1 channel blockers. In this article, we review features of both channels were summarized in a recent the functional roles of these channels in both naı¨ve cells review [15]. and memory cells, describe the development of selec- Following the discovery that Kþ channels are essential tive inhibitors of Kv1.3 and IKCa1 channels, and provide for T-cell function, several other Kþ channels have been a rationale for the potential therapeutic use of these implicated in the proliferation of a wide variety of normal inhibitors in immunological disorders. -
Fast K+ Currents from Cerebellum Granular Cells Are Completely Blocked by a Peptide Puri¢Ed from Androctonus Australis Garzoni
Biochimica et Biophysica Acta 1468 (2000) 203^212 www.elsevier.com/locate/bba Fast K currents from cerebellum granular cells are completely blocked by a peptide puri¢ed from Androctonus australis Garzoni scorpion venom Marzia Pisciotta a, Fredy I. Coronas b, Carlos Bloch c, Gianfranco Prestipino a;1;*, Lourival D. Possani b;1;2 a Istituto di Cibernetica e Bio¢sica, C.N.R., via De Marini 6, 16149 Genova, Italy b Biotechnology Institute-UNAM, Av. Universidad 2001, Cuernavaca 62210, Mexico c EMBRAPA/Cenargen, P.O. Box 02372, Brasilia, DF, Brazil Received 22 February 2000; received in revised form 25 May 2000; accepted 7 June 2000 Abstract A novel peptide was purified from the venom of the scorpion Androctonus australis Garzoni (abbreviated Aa1, corresponding to the systematic number alpha KTX4.4). It contains 37 amino acid residues, has a molecular mass of 3850 Da, is closely packed by three disulfide bridges and a blocked N-terminal amino acid. This peptide selectively affects the K currents recorded from cerebellum granular cells. Only the fast activating and inactivating current, with a kinetics similar to IA-type current, is completely blocked by the addition of low micromolar concentrations (Ki value of 150 nM) of peptide Aa1 to the external side of the cell preparation. The blockade is partially reversible in our experimental conditions. Aa1 blocks the channels in both the open and the closed states. The blockage is test potential independent and is not affected by changes in the holding potential. The kinetics of the current are not affected by the addition of Aa1 to the preparation; it means that the block is a simple `plugging mechanism', in which a single toxin molecule finds a specific receptor site in the external vestibule of the K channel and thereby occludes the outer entry to the K conducting pore. -
Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins
Biophysical Journal Volume 89 August 2005 1009–1019 1009 Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins Carolina Oliva, Vivian Gonza´lez, and David Naranjo Centro de Neurociencias de Valparaı´so, Facultad de Ciencias, Universidad de Valparaı´so, Valparaı´so, Chile ABSTRACT Voltage gated potassium channels open and inactivate in response to changes of the voltage across the membrane. After removal of the fast N-type inactivation, voltage gated Shaker K-channels (Shaker-IR) are still able to inactivate through a poorly understood closure of the ion conduction pore. This, usually slower, inactivation shares with binding of pore occluding peptide toxin two important features: i), both are sensitive to the occupancy of the pore by permeant ions or tetraethylammonium, and ii), both are critically affected by point mutations in the external vestibule. Thus, mutual interference between these two processes is expected. To explore the extent of the conformational change involved in Shaker slow inactivation, we estimated the energetic impact of such interference. We used kÿconotoxin-PVIIA (kÿPVIIA) and charybdotoxin (CTX) peptides that occlude the pore of Shaker K-channels with a simple 1:1 stoichiometry and with kinetics 100-fold faster than that of slow inactivation. Because inactivation appears functionally different between outside-out patches and whole oocytes, we also compared the toxin effect on inactivation with these two techniques. Surprisingly, the rate of macroscopic inactivation and the rate of recovery, regardless of the technique used, were toxin insensitive. We also found that the fraction of inactivated channels at equilibrium remained unchanged at saturating kÿPVIIA. -
Glycine311, a Determinant of Paxilline Block in BK Channels: a Novel Bend in the BK S6 Helix Yu Zhou Washington University School of Medicine in St
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2010 Glycine311, a determinant of paxilline block in BK channels: A novel bend in the BK S6 helix Yu Zhou Washington University School of Medicine in St. Louis Qiong-Yao Tang Washington University School of Medicine in St. Louis Xiao-Ming Xia Washington University School of Medicine in St. Louis Christopher J. Lingle Washington University School of Medicine in St. Louis Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Zhou, Yu; Tang, Qiong-Yao; Xia, Xiao-Ming; and Lingle, Christopher J., ,"Glycine311, a determinant of paxilline block in BK channels: A novel bend in the BK S6 helix." Journal of General Physiology.135,5. 481-494. (2010). http://digitalcommons.wustl.edu/open_access_pubs/2878 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Published April 26, 2010 A r t i c l e Glycine311, a determinant of paxilline block in BK channels: a novel bend in the BK S6 helix Yu Zhou, Qiong-Yao Tang, Xiao-Ming Xia, and Christopher J. Lingle Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO 63110 The tremorogenic fungal metabolite, paxilline, is widely used as a potent and relatively specific blocker of Ca2+- and voltage-activated Slo1 (or BK) K+ channels. The pH-regulated Slo3 K+ channel, a Slo1 homologue, is resistant to blockade by paxilline. -
Ligand and Voltage Gated Ion Channels
Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170314 Review Article Drug targets: ligand and voltage gated ion channels Nilan T. Jacob* Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), ABSTRACT Puducherry, India The elucidation of a drug target is one of the earliest and most important steps in the drug discovery process. Ion channels encompassing both the ligand gated Received: 03 December 2016 and voltage gated types are the second most common drug targets after G- Revised: 07 December 2016 Protein Coupled Receptors (GPCR). Ion channels are basically pore forming Accepted: 27 December 2016 membrane proteins specialized for conductance of ions as per the concentration gradient. They are further broadly classified based on the energy (ATP) *Correspondence to: dependence into active ion channels/pumps and passive ion channels. Gating is Dr. Nilan T. Jacob, the regulatory mechanism of these ion channels by which binding of a specific Email: molecule or alteration in membrane potential induces conformational change in [email protected] the channel architecture to result in ion flow or its inhibition. Thus, the study of ligand and voltage gated ion channels becomes an important tool for drug Copyright: © the author(s), discovery especially during the initial stage of target identification. This review publisher and licensee Medip aims to describe the ligand and voltage gated ion channels along with discussion Academy. This is an open- on its subfamilies, channel architecture and key pharmacological modulators. access article distributed under the terms of the Creative Keywords: Drug targets, Ion channels, Ligand gated ion channels, Receptor Commons Attribution Non- Commercial License, which pharmacology, Voltage gated ion channels permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Ion Channels: Structural Basis for Function and Disease
UC Irvine UC Irvine Previously Published Works Title Ion channels: structural basis for function and disease. Permalink https://escholarship.org/uc/item/39x307jx Journal Seminars in perinatology, 20(6) ISSN 0146-0005 Author Goldstein, SA Publication Date 1996-12-01 DOI 10.1016/s0146-0005(96)80066-8 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Ion Channels: Structural Basis for Function and Disease Steve A. N. Goldstein Ion channels are ubiquitous proteins that mediate nervous and muscular function, rapid transmem- brane signaling events, and ionic and fluid balance. The cloning of genes encoding ion channels has led to major strides in understanding the mechanistic basis for their function. These advances have shed light on the role of ion channels in normal physiology, clarified the molecular basis for an expanding number of diseases, and offered new direction to the development of rational therapeutic interventions. Copyright 1996 by W.B. Saunders Company on channels reside in the membranes of all by ion channels to be divided into two broad cells and control their electrical activity. 1 mechanistic groups: those resulting from loss of These proteins underlie subtle biological events channel function and those consequent to gain such as the response of a single rod cell to a of channel function. Three exemplary patho- beam of light, the activation of a T cell by its physiological correlates are examined, Long QT antigen, and the fast block to polyspermy of a syndrome, Liddle's syndrome and pseudohypo- fertilized ovum. -
Immune Drug Discovery from Venoms
Accepted Manuscript Immune drug discovery from venoms Rocio Jimenez, Maria P. Ikonomopoulou, J.A. Lopez, John J. Miles PII: S0041-0101(17)30352-5 DOI: 10.1016/j.toxicon.2017.11.006 Reference: TOXCON 5763 To appear in: Toxicon Received Date: 18 July 2017 Revised Date: 14 November 2017 Accepted Date: 18 November 2017 Please cite this article as: Jimenez, R., Ikonomopoulou, M.P., Lopez, J.A., Miles, J.J., Immune drug discovery from venoms, Toxicon (2017), doi: 10.1016/j.toxicon.2017.11.006. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Immune drug discovery from venoms Rocio Jimenez 1,2 , Maria P. Ikonomopoulou 2,3 , J.A. Lopez 1,2 and John J. Miles 1,2,3,4,5 1. Griffith University, School of Natural Sciences, Brisbane, Queensland, Australia 2. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia 3. School of Medicine, The University of Queensland, Brisbane, Australia 4. Centre for Biodiscovery and Molecular DevelopmentMANUSCRIPT of Therapeutics, AITHM, James Cook University, Cairns, Queensland, Australia 5. Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom Corresponding author: A/Prof John J. Miles, Molecular Immunology Laboratory, Centre for Biodiscovery and Molecular Development of Therapeutics, AITHM, James Cook University, Cairns, Queensland,ACCEPTED Australia E-mail: [email protected]. -
Synergistic Antinociception by the Cannabinoid Receptor Agonist Anandamide and the PPAR-Α Receptor Agonist GW7647
European Journal of Pharmacology 566 (2007) 117–119 www.elsevier.com/locate/ejphar Short communication Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-α receptor agonist GW7647 Roberto Russo a, Jesse LoVerme b, Giovanna La Rana a, Giuseppe D'Agostino a, Oscar Sasso a, ⁎ Antonio Calignano a, Daniele Piomelli b, a Department of Experimental Pharmacology, University of Naples, Naples, Italy b Department of Pharmacology, 360 MSRII, University of California, Irvine, California 92697-4625, United States Received 9 December 2006; received in revised form 27 February 2007; accepted 6 March 2007 Available online 19 March 2007 Abstract The analgesic properties of cannabinoid receptor agonists are well characterized. However, numerous side effects limit the therapeutic potential of these agents. Here we report a synergistic antinociceptive interaction between the endogenous cannabinoid receptor agonist anandamide and the synthetic peroxisome proliferator-activated receptor-α (PPAR-α) agonist 2-(4-(2-(1-Cyclohexanebutyl)-3-cyclohexylureido)ethyl)phenylthio)-2- methylpropionic acid (GW7647) in a model of acute chemical-induced pain. Moreover, we show that anandamide synergistically interacts with the large-conductance potassium channel (KCa1.1, BK) activator isopimaric acid. These findings reveal a synergistic interaction between the endocannabinoid and PPAR-α systems that might be exploited clinically and identify a new pharmacological effect of the BK channel activator isopimaric acid. © 2007 Elsevier B.V. -
For Toxicon Manuscript Draft Manuscript Number: Title
Elsevier Editorial System(tm) for Toxicon Manuscript Draft Manuscript Number: Title: Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels Article Type: Research Paper Keywords: Margatoxin, MgTx, non-selective, Kv1.3, Kv1.2 Corresponding Author: Prof. Gyorgy Panyi, MD PhD Corresponding Author's Institution: University of Debrecen, Medical and Health Science Center First Author: Adam Bartok Order of Authors: Adam Bartok; Agnes Toth, Ph.D.; Sandor Somodi, M.D., Ph.D.; Tibor G Szanto, Ph.D.; Peter Hajdu, Ph.D.; Gyorgy Panyi, MD PhD; Zoltan Varga, Ph.D. Abstract: During the last few decades many short-chain peptides have been isolated from the venom of different scorpion species. These toxins inhibit a variety of K+ channels by binding to and plugging the pore of the channels from the extracellular side thereby inhibiting ionic fluxes through the plasma membrane. The high affinity and selectivity of some toxins promote these peptides to become lead compounds for potential therapeutic use. Voltage-gated K+ channels can be classified into several families based on their gating properties and sequence homology. Members of a given family may have high sequence similarity, such as Kv1.1, Kv1.2 and Kv1.3 channels, therefore selective inhibitors of one specific channel are quite rare. The lack of selectivity of such peptides and the inhibition of more types of channels might lead to undesired side effects upon therapeutic application or may lead to incorrect conclusion regarding the role of a particular ion channel in a physiological or pathophysiological response either in vitro or in vivo. Margatoxin (MgTx) is often considered as a high affinity and selective inhibitor of the Kv1.3 channel. -
Design of a Truncated Cardiotoxin‑I Analogue with Potent Insulinotropic
Design of a Truncated Cardiotoxin‑I Analogue with Potent Insulinotropic Activity Thi Tuyet Nhung Nguyen, Benjamin Folch, Myriam Letourneau, Nam Hai Truong, Nicolas Doucet, Alain Fournier, David Chatenet To cite this version: Thi Tuyet Nhung Nguyen, Benjamin Folch, Myriam Letourneau, Nam Hai Truong, Nicolas Doucet, et al.. Design of a Truncated Cardiotoxin‑I Analogue with Potent Insulinotropic Activity. Journal of Medicinal Chemistry, American Chemical Society, 2014, 57 (6), pp.2623-33. 10.1021/jm401904q. hal-01177382 HAL Id: hal-01177382 https://hal.archives-ouvertes.fr/hal-01177382 Submitted on 14 Sep 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Design of a Truncated Cardiotoxin-I Analogue with Potent Insulinotropic Activity Thi Tuyet Nhung Nguyen†‡§, Benjamin Folch†∥⊥, Myriam Létourneau†§, Nam Hai Truong‡, Nicolas Doucet†∥⊥, Alain Fournier*†§, and David Chatenet*†§ † INRS−Institut Armand-Frappier, Université du Québec, 531 Boulevard des Prairies Ville de Laval, Québec H7 V 1B7, QuébecCanada ‡ Vietnam Academy of Science and Technology, Institute